Early use of posaconazole in the successful treatment of rhino-orbital mucormycosis caused by Rhizopus oryzae

Journal of Infection

Volumn 55, Issue 3, 2007, Pages

  Kok, Jen ^a   Gilroy, Nicole ^a   Halliday, Catriona ^a,b   Lee, Ok Cha ^b   Novakovic, Daniel ^a   Kevin, Patrick ^a   Chen, Sharon ^a,b  

^a WESTMEAD HOSPITAL   (Australia)

^b Western Sydney Area Health Service   (Australia)

Author keywords

Posaconazole; Rhino cerebral mucormycosis; Rhizopus oryzae

Indexed keywords

AMPHOTERICIN; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; AZATHIOPRINE; C REACTIVE PROTEIN; CLINDAMYCIN; CREATININE; CYCLOSPORIN; FLUCONAZOLE; GALLIUM CITRATE GA 67; GLUCOSE; HEMOGLOBIN A1C; ITRACONAZOLE; KETONE; MEROPENEM; METICILLIN; POSACONAZOLE; PREDNISOLONE; PYRROLE DERIVATIVE; TECHNETIUM 99M; TIMENTIN; VORICONAZOLE;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; BONE SCINTISCANNING; CADAVER KIDNEY; CASE REPORT; CHRONIC ALLOGRAFT NEPHROPATHY; CHRONIC KIDNEY FAILURE; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; DEBRIDEMENT; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE COURSE; DRUG TOLERABILITY; EARLY INTERVENTION; ENDOSCOPIC SURGERY; ENTEROBACTER CLOACAE; EXPERIENCE; FACE EDEMA; FACE PAIN; FEMALE; FUNGUS HYPHAE; FUNGUS IDENTIFICATION; HISTOPATHOLOGY; HOSPITAL DISCHARGE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY TRANSPLANTATION; LABORATORY TEST; MALE; MAXILLARY SINUS; MINIMUM INHIBITORY CONCENTRATION; MUCORMYCOSIS; NEPHRECTOMY; NOSE INFECTION; NOSE SURGERY; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOCYTOMA; ORBIT EDEMA; ORBIT INFECTION; PATHOGENESIS; PHYSICAL EXAMINATION; PULMONARY HYPERTENSION; RHIZOPUS ORYZAE; STAPHYLOCOCCUS AUREUS; TISSUE CULTURE; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL IMPAIRMENT;

AGED; ANTIFUNGAL AGENTS; ETHMOID SINUSITIS; FEMALE; HUMANS; MALE; MAXILLARY SINUSITIS; MIDDLE AGED; MUCORMYCOSIS; RHIZOPUS; TREATMENT OUTCOME; TRIAZOLES;

EID: 34547851205     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2007.05.178     Document Type: Article

References (24)

1. Ribes J.A., Vanover-Sama C.L., and Baker D.J. Zygomycetes in human disease. Clin Microbiol Rev 13 (2000) 236-301
2. Chakrabati A., Das A., Sharma A., Panda N., Das S., Gupta K.L., et al. Ten years' experience in zygomycosis at a tertiary care centre in India. J Infect 42 (2001) 261-266
3. Roden M.M., Zaoutis T.E., Buchanan W.L., Knudsen T.A., Sarkissova T.A., Schaufele M., et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 41 (2005) 634-653
4. Dannaoui E., Meletiadis J., Mouton J.W., Meis J.F.G.M., Verweij P.E., and the Eurofung Network. In vitro susceptibilities of zygomycetes to conventional and new antifungals. J Antimicrob Chemother 51 (2003) 45-52
5. Sun Q.N., Najvar L.K., Bocanegra R., Loebenberg D., and Graybill J.R. In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model. Antimicrob Agents Chemother 46 (2002) 2310-2312
6. Pfaller M.A., Messer S.A., Hollis R.J., and Jones R.N. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother 46 (2002) 1032-1037
7. Greenberg R.N., Mullane K., van Burik J.-.A.H., Raad I., Abzug M.J., Anstead G., et al. Posacoanazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 50 (2006) 126-133
8. Raad I, Chapman S, Bradsher R, Morrison V, Goldman M, Graybil J, et al. Posaconazole (POS) salvage therapy for invasive fungal infections (IFI). Poster presented at the forty-fourth annual interscience conference on antimicrobial agents and chemotherapy (ICAAC). Washington, DC, USA; Oct 30-Nov 2, 2004.
9. Tobon A.M., Arango M., Fernandez D., and Restrepo A. Mucormycosis (zygomycosis) in a heart-kidney transplant recipient: recovery after posaconazole therapy. Clin Infect Dis 36 (2003) 1488-1491
10. Garbino J., Uckay I., Amini K., Puppo M., Richter M., and Lew D. Absidia posttraumatic infection: successful treatment with posaconazole. J Infect 51 (2005) e135-e138
11. Gilman A.L., Serrano A., Skelley J., and Zwick D. Successful treatment of pulmonary zygomycosis with posaconazole in a recipient of a haploidentical donor stem cell transplant. Pediatr Blood Cancer 47 (2006) 959-963
12. Leather H.L., Correll T.A., Meyer C.L., Schmalfuss I.M., and Wingard J.R. Treatment of zygomycosis with posaconazole in a patient with acute myeloid leukemia. Clin Adv Hematol Oncol 3 (2005) 773-778
13. de Hoog G.S., Guarro J., Gene J., and Figueras M.J. Atlas of clinical fungi. 2nd ed. (2000), Centraalbureau voor Schimmelcultures, Utrecht, The Netherlands
14. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard M38-A (2002), National Committee for Clinical Laboratory Standards, Wayne, PA
15. Dhiwakar M., Thakar A., and Bahadur S. Improving outcomes in rhinocerebral mucormycosis-early diagnostic pointers and prognostic factors. J Laryngol Otol 117 (2003) 861-865
16. DelGaudio J.M., Swain R.E., Kingdom T.T., Muller S., and Hudgins P.A. Computer tomographic findings in patients with invasive fungal sinusitis. Arch Otolaryngol Head Neck Surg 129 (2003) 236-240
17. Uchida K., Yokota N., and Yamaguchi H. In vitro antifungal activity of posaconazole against fungi. Int J Antimicrob Agents 18 (2001) 167-172
18. Dannaoui E., Meis J.F., Leobenberg D., and Verweij P.E. Activity of posaconazole in treatment of experimental disseminated zygomycosis. Antimicrob Agents Chemother 47 (2003) 3647-3650
19. Herbrecht R. Posaconazole: a potent, extended-spectrum triazole antifungal for the treatment of serious fungal infections. Int J Clin Pract 58 (2004) 612-624
20. Hof H. A new, broad-spectrum azole antifungal: posaconazole-mechanisms of action and resistance, spectrum of activity. Mycoses 49 Suppl. 1 (2006) 2-6
21. Rickerts V., Atta J., and Herrmann S. Successful treatment of disseminated mucormycosis with a combination of liposomal amphotericin B and posaconazole in a patient with acute myeloid leukaemia. Mycoses 49 Suppl. 1 (2006) 27-30
22. Courtney R., Wexler D., Radwanski E., Lim J., and Laughlin M. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol 57 (2004) 218-222
23. Torres H.A., Hachem R.Y., Chemaly R.F., Kontoyiannis D.P., and Raad I.I. Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect Dis 5 (2006) 775-785
24. Groll A.H., and Walsh T.J. Antifungal efficacy and pharmacodynamics of posaconazole in experimental models of invasive fungal infections. Mycoses 49 Suppl. 1 (2006) 7-16